Patrick M. Boland

Rutgers, The State University of New Jersey

Also affiliated with Rutgers Cancer Institute

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 15 papers. Top paper: “Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer”.

Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer

JAMA Network Open(2022)10.1001/jamanetworkopen.2021.49040

N/A

3.5DataRank · unranked

127 citations

Fang‐Shu Ou, Tyler Zemla, Þorvarður R. Hálfdánarson, Heinz‐Josef Lenz, Rimini Breakstone +11 more

First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study

European Journal of Cancer(2021)10.1016/j.ejca.2021.03.028

N/A

0.604DataRank · unranked

55 citations

Tanios Bekaii‐Saab, Patrick M. Boland, Farshid Dayyani, Teresa Macarulla, Kabir Mody +8 more

Sensitivity of colorectal or pancreatic cancers with high DDX5 and mutations in Kras and p53 genes to FL118 treatment.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e16102

N/A

0DataRank · unranked

2 citations

Wenjie Wu, Jianqun Liao, Sreevidya Santha, Leman Aljahdali, Jue Wang +5 more

Outcomes of patients with borderline resectable and resectable pancreatic adenocarcinoma treated with neoadjuvant three-week course chemoradiotherapy using capecitabine-based versus gemcitabine-based concurrent chemotherapy

Journal of Gastrointestinal Oncology(2021)10.21037/jgo-21-503

N/A

0DataRank · unranked

2 citations

Swati Mamidanna, Anupama Chundury, Mutlay Sayan, H. Richard Alexander, David A. August +11 more

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer:NRG-GI005 (COBRA).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.tps148

N/A

0DataRank · unranked

5 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +7 more

Phase II/III study of Circulating tumOr DNA as a predictive BiomaRker in Adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps3622

N/A

0DataRank · unranked

2 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +7 more

FL118, acting as a ‘molecular glue degrader’, binds to, dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c‐Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy

Clinical and Translational Medicine(2022)10.1002/ctm2.881

N/A

0DataRank · unranked

40 citations

Wenjie Wu, Ieman Aljahdali, Jianqun Liao, Sreevidya Santha, Christos Fountzilas +3 more

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.tps233

N/A

0DataRank · unranked

3 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +8 more

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps259

N/A

0DataRank · unranked

1 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +8 more

Trial in progress: A phase II study (with safety run-in) of evorpacept (ALX148), cetuximab, and pembrolizumab in patients with refractory microsatellite-stable metastatic colorectal cancer (AGICC-ALX148 21CRC01).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps257

N/A

0DataRank · unranked

0 citations

Junxiao Hu, Patrick J. Blatchford, Todd M. Pitts, Alexis D. Leal, Sunnie S. Kim +7 more

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps3625

N/A

0DataRank · unranked

0 citations

Greg Yothers, Scott Kopetz, Shannon L. Puhalla, Peter C. Lucas, Atif Iqbal +8 more

Oncointerpreter.ai enables interactive, personalized summarization of cancer diagnostics data

Journal of the American Medical Informatics Association(2024)10.1093/jamia/ocae284

N/A

0DataRank · unranked

4 citations

Brett L. Ecker, Patrick M. Boland, Saum Ghodoussipour, Gregory R Riedlinger, Subhajyoti De +1 more

NRG-GI005 (COBRA): Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.4_suppl.tps261

N/A

0DataRank · unranked

17 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +7 more

Results of a phase 2 study of evorpacept (E, ALX148), cetuximab (C), and pembrolizumab (P) in patients with refractory microsatellite stable metastatic colorectal cancer (MSS CRC).

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.3530

N/A

0DataRank · unranked

1 citations

Patrick J. Blatchford, Junxiao Hu, Todd M. Pitts, Adrie Van Bokhoven, Hannah R. Robinson +13 more

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps4121

N/A

0DataRank · unranked

4 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +7 more